Elevation Oncology, Inc.

Equities

ELEV

US28623U1016

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 14/05/2024 am IST			5-day change	1st Jan Change
3.54 ^USD	+7.93%		-5.35%	+559.22%

02/05	Elevation Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05/04	Elevation Oncology, Inc. Announces Management Changes	CI

Elevation Oncology, Inc. Plans to Provide an Update from Its Ongoing Phase 1 Trial of EO-3021

January 05, 2024 at 06:10 pm IST

On January 5, 2024, Elevation Oncology, Inc. announced that it plans to provide an update from its ongoing Phase 1 trial of EO-3021, an anti-Claudin 18.2 antibody-drug conjugate (ADC"), in mid-2024, with additional data expected in the first half of 2025. The Company also announced that it plans to evaluate EO-3021 in combination with both immunotherapy and targeted agents, with further details on its combination study expected in the first half of 2024. In addition, the Company announced that it is currently evaluating a HER3-targeting ADC program and plans to nominate a development candidate in 2024.

The Company further reported that it expects its cash, cash equivalents and marketable securities as of September 30, 2023 to be sufficient to fund its current operations into the second half of 2025.

Latest news about Elevation Oncology, Inc.

Elevation Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05	CI
Elevation Oncology, Inc. Announces Management Changes	06/04	CI
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	28/03	MT
Wedbush Raises Elevation Oncology's PT to $8 From $5, Continues to See 'Intriguing' Opportunity in Shares; Keeps Outperform Rating	07/03	MT
Elevation Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06/03	CI
Elevation Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03	CI
Elevation Oncology, Inc. Appoints Julie Cherrington and Alan Sandler to Board of Directors	04/03	CI
JMP Securities Starts Elevation Oncology' With Market Outperform Rating	01/03	MT
Elevation Oncology Expands Phase 1 Study of Potential Solid Tumor Treatment	22/02	MT
Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan	22/02	CI
HC Wainwright Adjusts Elevation Oncology Price Target to $6 From $1.50, Maintains Buy Rating	20/02	MT
Elevation Oncology Announces Appointment of Darcy Mootz to Its Board of Directors and as Member of the Compensation Committee	22/01	CI
Elevation Oncology Says It Has Funds to Continue Operations Into H2 2025	06/01	MT
Elevation Oncology, Inc. Plans to Provide an Update from Its Ongoing Phase 1 Trial of EO-3021	05/01	CI
Elevation Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02/11	CI
Certain Restricted Stock Units of Elevation Oncology, Inc. are subject to a Lock-Up Agreement Ending on 7-SEP-2023.	07/23/07	CI
Certain Warrants of Elevation Oncology, Inc. are subject to a Lock-Up Agreement Ending on 7-SEP-2023.	07/23/07	CI
Certain Pre-funded Warrants of Elevation Oncology, Inc. are subject to a Lock-Up Agreement Ending on 7-SEP-2023.	07/23/07	CI
Certain Common Stock of Elevation Oncology, Inc. are subject to a Lock-Up Agreement Ending on 7-SEP-2023.	07/23/07	CI
Elevation Oncology, Inc. Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating E)-3021	16/23/16	CI
Certain Restricted Stock Units of Elevation Oncology, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2023.	08/23/08	CI
Certain Warrants of Elevation Oncology, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2023.	08/23/08	CI
Certain Pre-funded Warrants of Elevation Oncology, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2023.	08/23/08	CI
Certain Common Stock of Elevation Oncology, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2023.	08/23/08	CI
Wedbush Trims Elevation Oncology's Price Target to $5 From $6, Keeps Outperform Rating	04/23/04	MT

Chart Elevation Oncology, Inc.

Duration

Period

More charts

Company Profile

Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors.

Sector

Biotechnology & Medical Research

Calendar

09:00pm - Citizens JMP Life Sciences Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.54 USD

Average target price

7.75 USD

Spread / Average Target

+118.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ELEVATION ONCOLOGY, INC.	+559.22%	19Cr
VERTEX PHARMACEUTICALS INCORPORATED	+5.66%	11TCr
REGENERON PHARMACEUTICALS, INC.	+11.23%	11TCr
ARGENX SE	-0.38%	2.19TCr
BIONTECH SE	-12.15%	2.23TCr
GENMAB A/S	-7.66%	1.86TCr
WUXI APPTEC CO., LTD.	-36.52%	1.81TCr
BEIGENE, LTD.	-10.09%	1.7TCr
NEUROCRINE BIOSCIENCES, INC.	+3.33%	1.37TCr
SAREPTA THERAPEUTICS, INC.	+36.58%	1.24TCr

Bio Therapeutic Drugs